Azenta (NASDAQ:AZTA) Releases Earnings Results, Misses Expectations By $0.14 EPS
by Scott Moore · The Cerbat GemAzenta (NASDAQ:AZTA – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.14), FiscalAI reports. The company had revenue of $144.80 million for the quarter, compared to the consensus estimate of $148.26 million. Azenta had a positive return on equity of 1.43% and a negative net margin of 10.34%.The business’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.01 EPS.
Azenta Trading Up 1.2%
AZTA traded up $0.28 during trading on Tuesday, reaching $24.61. 1,847,559 shares of the company’s stock were exchanged, compared to its average volume of 809,043. The stock has a market capitalization of $1.13 billion, a PE ratio of -18.23 and a beta of 1.43. The firm has a fifty day moving average price of $23.56 and a two-hundred day moving average price of $30.23. Azenta has a one year low of $19.87 and a one year high of $41.73.
Analyst Ratings Changes
Several equities research analysts have issued reports on AZTA shares. TD Cowen restated a “hold” rating on shares of Azenta in a research report on Wednesday, February 4th. Wall Street Zen cut shares of Azenta from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Evercore lowered their target price on shares of Azenta from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Jefferies Financial Group lowered their target price on shares of Azenta from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Azenta in a research report on Tuesday, March 17th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $41.33.
Get Our Latest Analysis on Azenta
Institutional Trading of Azenta
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in shares of Azenta by 9.9% in the 4th quarter. Millennium Management LLC now owns 1,866,531 shares of the company’s stock valued at $62,081,000 after purchasing an additional 167,969 shares during the last quarter. State Street Corp boosted its position in shares of Azenta by 1.4% during the 4th quarter. State Street Corp now owns 1,732,755 shares of the company’s stock valued at $57,631,000 after purchasing an additional 24,062 shares in the last quarter. American Capital Management Inc. boosted its position in shares of Azenta by 23.2% during the 4th quarter. American Capital Management Inc. now owns 1,021,436 shares of the company’s stock valued at $33,973,000 after purchasing an additional 192,116 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Azenta by 49.3% in the second quarter. Ameriprise Financial Inc. now owns 722,576 shares of the company’s stock valued at $22,241,000 after purchasing an additional 238,444 shares in the last quarter. Finally, Quantinno Capital Management LP raised its holdings in shares of Azenta by 192.0% during the second quarter. Quantinno Capital Management LP now owns 713,939 shares of the company’s stock valued at $21,975,000 after purchasing an additional 469,447 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.
Azenta Company Profile
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.